
Qian Wang
Articles
-
2 months ago |
mdpi.com | Yan Gao |Dandan Wang |Qian Wang |Jinfeng Wang
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Dec 31, 2024 |
mdpi.com | Qian Wang
4. Experimental Results and AnalysisThis section first examines the effectiveness of two improvement strategies integrated into HERIME. Then, the performance of HERIME is analyzed and compared with several classical advanced algorithms together with some high-performance improved algorithms. 4.1. Experimental Setup and Evaluation CriteriaAll experiments were conducted on a CPU with properties of AMD R9 7950X @ 5.20 GHz, 64 GB RAM, running on the Windows 10 operating system.
-
Dec 28, 2024 |
arthritis-research.biomedcentral.com | Yupei Zhang |Nan Jiang |Xinwang Duan |Jian Xu |Lijun Wu |Wei Wei | +9 more
-
Dec 17, 2024 |
cell.com | Yiming Shi |Jiaming Zhang |Xingyi Li |Yuchong Han |Jiangheng Guan |Yilin Li | +14 more
Keywordsintrinsically photosensitive retinal ganglion cellsorientation selectivityprimary visual cortexvisual discriminabilityGet full text accessLog in, subscribe or purchase for full access. References1. Chang, L. ∙ Tsao, D.Y.The Code for Facial Identity in the Primate BrainCell. 2017; 169:1013-1020.e142. Simoncelli, E.P. ∙ Olshausen, B.A.Natural image statistics and neural representationAnnu. Rev. Neurosci. 2001; 24:1193-12163.
-
Dec 5, 2024 |
biorxiv.org | Qian Wang |Yicheng Guo |Ryan G. Casner |Jian Yu
AbstractSARS-CoV-2 has largely evolved to resist antibody pressure, with each successive viral variant becoming more and more resistant to serum antibodies in the population. This evolution has rendered inactive all therapeutic monoclonal antibodies previously authorized, and it is now threatening the remaining clinical product for immunoprophylaxis against COVID-19.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →